I am pleased to announce "Cardiovascular Therapeutics," a quarterly feature that will update readers on recent developments in cardiovascular drug therapy.
Cardiovascular disease remains the number one killer in the US. More clinical outcome trials have been conducted in cardiology than in any other field of medicine, and our knowledge is rapidly expanding. The armamentarium of cardiovascular drugs is augmented by new or developing delivery approaches, including gene therapy. There are tremendous opportunities for pharmacists in the prevention and treatment of cardiovascular disease if they stay current with developments in drug therapy.
The author of "Cardiovascular Therapeutics" is Patricia A. Howard, PharmD, FCCP, BCPS with Added Qualifications in Cardiology. Dr. Howard is professor and vice chair of Pharmacy Practice at the University of Kansas School of Pharmacy and has a practice site at the University of Kansas Medical Center in Kansas City, Kansas. She is also professor of medi-cine in the Department of Cardiovascular Medicine at the University of Kansas School of Medicine.
Dr. Howard's responsibilities include providing clinical pharmacy services to the Cardiovascular Service at Kansas University Hospital, teaching the cardiology clerkship and related didactic courses for PharmD students, and participating in research projects related to cardiovascular drug therapy. In 2001, Dr. Howard received the W. T. Kemper Fellowship for Teaching Excellence at the University of Kansas and the Kansas Society of Hospital Pharmacists Board Award for Innovative Practice. She has also made significant contributions to the cardiovascular pharmacotherapy literature.
The first Cardiovascular Therapeutics feature, "Efficacy of Beta Blockers in Severe Heart Failure," appears in this issue. The use of beta blockers, which are negative inotropes, for the treatment of heart failure represents a major paradigm shift; these drugs are now a cornerstone of therapy for mild-to-moderate failure. This article presents the findings of recent studies (eg, COPERNICUS) that extend the population of patients with heart failure who may benefit from beta blockade. There are significant new roles for pharmacists in developments like this one.
Future topics under consideration for the the feature include (but are not limited to) the use of thrombolytics in combination with GP IIb/IIIa inhibitors for ST elevation-myocardial infarction, an update on new bolus thrombolytics, ARBs for heart failure and the role of IV amiodarone for ventricular arrhythmias.
We at Facts and Comparisons welcome Dr. Howard's Cardiovascular Therapeutics feature to Hospital Pharmacy.
Please e-mail me at dcada@drugfacts.com if you would like to suggest a related topic of general interest to our readership.
-Dennis Cada, PharmD, FASHP, FASCP Editor-in-Chief, Hospital Pharmacy
CALL FOR MANUSCRIPTS
Hospital Pharmacy is currently accepting articles for publication. The desired subject matter encompasses all areas of interest to pharmacists practicing in the inpatient and outpatient settings within hospitals, longterm care facilities, home care, and other health-system settings. Share with the Hospital Pharmacy readership how your facility is dealing with current trends in pharmaceutical care practice. The most frequently submitted types of articles include Original Articles, Review Articles, Brief Reports, Case Reports, and Letters to the Editor. All manuscripts are subject to review by qualified independent readers and the editors. Articles will be accepted for publication if they are judged to represent an important contribution to the literature.
If you are interested in submitting a manuscript, please direct your query to Dennis Cada, PharmD, FASHP, FASCP at hospitalpharmacy@drugfacts.com or visit www.hospitalpharmacyjournal.com to view the Notice to Authors.
